Critical Path Public Private Partnerships

The summary for the Critical Path Public Private Partnerships grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Food Drug Administration, which is the U.S. government agency offering this grant.

Critical Path Public Private Partnerships: As part of its Critical Path Initiative, FDA recognizes the need for collaborations established under the terms and conditions of a cooperative agreement, whereby existing resources and expertise can be used to the fullest extent possible. The Critical Path Institute has developed 8 individual consortia – the Coalition Against Major Disease Consortium (CAMD), the Multiple Sclerosis Outcome Assessment Consortium (MSOAC), the Patient Reported Outcomes Consortium (PRO), the Electronic Patient Reported Outcomes Consortium (ePRO), the Coalition for Accelerating Standards and Therapies (CFAST), the Predictive Safety Testing Consortium (PSTC), the Polycystic Kidney Disease Outcome Consortium (PKD), and the Critical Path to TB Drug Regimens Consortium (CPTR). These consortia have been active in developing biomarkers and Clinical Outcome Assessment Tools for Qualification under the FDA’s Drug Development Tool Qualification Program. The goals of this program are to maintain the administrative and scientific infrastructure of these consortia efforts while continuing to support the creation and execution of ongoing and new projects (such as a Neonatal Consortium) under the FDA's Critical Path Initiative.